Prospective study of fecal colonization by extended-spectrum-β- lactamase-producing Escherichia coli in neutropenic patients with cancer

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 11, 2008, Pages 4187-4190

  Calatayud, L ^a,b   Arnan, M ^c   Linares J ^a,b   Dominguez, M A ^a   Gudiol, C ^a   Carratala J ^a   Batlle, M ^d   Ribera, J M ^d   Gudiol, F ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Hospital Duran y Reynals   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EXTENDED SPECTRUM BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; CANCER PATIENT; ENZYME SYNTHESIS; ESCHERICHIA COLI; FECES MICROFLORA; HUMAN; MAJOR CLINICAL STUDY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS;

BETA-LACTAM RESISTANCE; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FECES; HUMANS; NEOPLASMS; NEUTROPENIA; PROSPECTIVE STUDIES;

EID: 55849134079     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00367-08     Document Type: Article

References (23)

1. Bonnet, R. 2004. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother. 48:1-14.
2. Carratalà, J., A. Fernández-Sevilla, F. Tubau, M. A. Domínguez, and F. Gudiol. 1996. Emergence of fluoroquinolone- resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob. Agents Chemother. 40:503-505.
3. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing; 15th informational supplement. CLSI/NCCLS document M100-369 S15. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Fang, H., F. Ataker, G. Hedin, and K. Dornbusch. 2008. Molecular epidemiology of extended-spectrum β-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006. J. Clin. Microbiol. 46:707-712.
5. Hughes, W. T., D. Armstrong, G. P. Bodey, E. J. Bow, A. E. Brown, T. Calandra, R. Feld, P. A. Pizzo, K. V. Rolston, J. L. Shenep, and L. S. Young. 2002. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. 15:730-751.
6. Jacoby, G. A., and L. Sutton. 1991. Properties of plasmids responsible for production of extended spectrum β-lactamases. Antimicrob. Agents Chemother. 35:164-169.
7. Jarlier, V., M. H. Nicolas, G. Fournier, and A. Philippon. 1988. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev. Infect. Dis. 10:867-878.
8. Kang, C.-I., S.-H. Kim, W. B. Park, K.-D. Lee, H.-B. Kim, E.-C. Kim, M.-D. Oh, and K.-W. Choe. 2004. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob. Agents Chemother. 48:4574-4581.
9. Kim, Y. K., H. Pai, H. J. Lee, S. E. Park, E. H. Choi, J. Kim, J. H. Kim, and E. C. Kim. 2002. Bloodstream infections by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob. Agents Chemother. 46:1481-1491.
10. Livermore, D. M., R. Cantón, M. Gniadkowski, P. Nordmann, G. M. Rossolini, G. Arlet, J. Ayala, T. M. Coque, I. Kern-Zdanowicz, F. Luzzaro, L. Poirel, and N. Woodford. 2007. CTX-M: changing the face of ESBLs in Europe. J. Antimicrob. Chemother. 59:165-174.
11. Mirelis, B., F. Navarro, E. Miró, R. J. Mesa, P. Coll, and G. Prats. 2003. Community transmission of extended-spectrum betalactamases. Emerg. Infect. Dis. 9:1024-1025.
12. Miró, E., B. Mirelis, F. Navarro, A. Rivera, R. J. Mesa, M. C. Roig, L. Gómez, and P. Coll. 2005. Surveillance of extended-spectrum beta-lactamases from clinical samples and faecal carriers in Barcelona, Spain. J. Antimicrob. Chemother. 56:1152-1155.
13. Morosini, M. I., M. García-Castillo, T. M. Coque, A. Valverde, A. Novais, E. Loza, F. Baquero, and R. Cantón. 2006. Antibiotic coresistance in extended-spectrum-β-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob. Agents Chemother. 50:2695-2699.
14. Mutnick, A. H., J. T. Kirby, R. N. Jones, et al. 2003. Cancer resistance surveillance program: initial results from hematology-oncology centers in North America. Ann. Pharmacother. 37:47-56.
15. Paterson, D. L., and R. A. Bonomo. 2005. Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 18:657-686.
16. Peña, C., C. Gudiol, F. Tubau, M. Saballs, M. Pujol, M. A. Dominguez, L. Calatayud, J. Ariza, and F. Gudiol. 2006. Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients. Clin. Microbiol. Infect. 12:279-284.
17. Pitout, J. D., P. Nordmann, K. B. Laupland, and L. Poirel. 2005. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J. Antimicrob. Chemother. 56:52-59.
18. Rodríguez-Baño, J., M. D. Navarro, L. Romero, L. Martinez-Martinez, M. A. Muniain, E. J. Perea, R. Perez-Cano, and A. Pascual. 2004. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J. Clin. Microbiol. 42:1089-1094.
19. Rodríguez-Baño, J., M. D. Navarro, L. Romero, M. A. Muniain, E. J. Perea, R. Pérez-Cano, J. R. Hernández, and A. Pascual. 2006. Clinical and molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin. Infect. Dis. 42:37-45.
20. Sabaté, M., E. Miró, F. Navarro, C. Verges, R. Aliaga, B. Mirelis, and G. Prats. 2002. Beta-lactamases involved in resistance to broad-spectrum cephalosporins in Escherichia coli and Klebsiella spp. clinical isolates collected between 1994 and 1996, in Barcelona (Spain). J. Antimicrob. Chemother. 49:989-997.
21. Siu, L. K., P.-L. Lu, P.-R. Hsueh, F. M. Lin, S.-C. Chang, K.-T. Luh, M. Ho, and C.-Y. Lee. 1999. Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric oncology ward: clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes. J. Clin. Microbiol. 37:4020-4027.
22. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
23. Valverde, A., T. Coque, M. P. Sánchez-Moreno, A. Rollán, F. Baquero, and R. Cantón. 2004. Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J. Clin. Microbiol. 42:4769-4775.